Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 1998
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytomaF Silvestri, G Barillari, R Fanin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 16, 2023
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)P Di Nardo, D Basile, A Siciliano, et al.
Breast Cancer Research and Treatment|November 7, 2012
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozoleG Lunardi, P Piccioli, P Bruzzi, et al.
European Review for Medical and Pharmacological Sciences|March 28, 2019
Biological properties of Cakile maritima Scop. (Brassicaceae) extractsV Fuochi, I Barbagallo, A Distefano, et al.
ESMO Open|January 7, 2026
Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trialsR Borea, E Blondeaux, L Carmisciano, et al.
British Journal of Cancer|January 23, 2014
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozoleV Sini, G Lunardi, M Cirillo, et al.
Cancer Treatment Reviews|January 13, 2023
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical reviewF Miglietta, A Fabi, D Generali, et al.
Obesity Surgery|October 4, 2005
BioEnterics Intragastric Balloon: The Italian Experience with 2,515 PatientsA Genco, T Bruni, S B Doldi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2021
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognosticationD Miles, E Ciruelos, A Schneeweiss, et al.
Pageof 11